Resources
Peer review articles, research & other resources related to our blood-based mRNA molecular cancer diagnostics
A collection of peer-reviewed articles, scientific and mainstream press coverage, corporate and customer presentations as well as press releases to help doctors, oncologists, patients, and others understand the benefits of Wren’s mRNA-based molecular blood-biopsy diagnostics. If you are looking for something specific, use the quick links below or the search bar in the header.
Featured Resources
NETest Validated as Reliable Biomarker for PRRT
Recent research spearheaded by Lisa Bodei, MD and published in the Journal of Nuclear Medicine (April '23) has validated the role of the NETest as a predictor of the effectiveness of PRRT in treating NETs.
The Prognostic and Predictive role of the NETest
The NETest is a standardized and reproducible liquid biopsy for neuroendocrine tumors (NETs). It evaluates the expression of 51 NET genes by real-time polymerase chain reaction, providing an accurate molecular profile of the neoplasm.
Annals of Surgical Oncology – A Promising Biomarker for Pancreatic Neuroendocrine Tumours
ASO Author Reflections: Circulating Neuroendocrine Gene Transcripts (NETest): A Promising Biomarker for Pancreatic Neuroendocrine Tumours (PanNET)
NETest Peer Review Research
A collection of over 10 years of global peer-reviewed research on topics related to our NET diagnostics that detect neuroendocrine tumors, illuminate treatment options, and help monitor therapy.
Neuroendocrinology – NETest Sensitivity and Specificity Validation Study
Secretory tumor markers traditionally measured in patients with neuroendocrine tumors (NET) are lacking sensitivity and specificity, and consequently they are of limited clinical utility.
The NETest: A meta-analysis of the accuracy of an mRNA blood-based neuroendocrine tumor biomarker
Analysis of ten studies indicates the NETest is an accurate (>95%) biomarker suitable for clinical use in NET disease management, exhibiting utility as an IVD to establish a diagnosis and monitor therapeutic efficacy.
The Prognostic and Predictive role of the NETest
The NETest is a standardized and reproducible liquid biopsy for neuroendocrine tumors (NETs). It evaluates the expression of 51 NET genes by real-time polymerase chain reaction, providing an accurate molecular profile of the neoplasm.
Annals of Surgical Oncology – A Promising Biomarker for Pancreatic Neuroendocrine Tumours
ASO Author Reflections: Circulating Neuroendocrine Gene Transcripts (NETest): A Promising Biomarker for Pancreatic Neuroendocrine Tumours (PanNET)
Why the NETest?
Questions about the NETest answered with clinical or peer-reviewed research.
How can the NETest help me in the management of NET disease?
A1. DO I HAVE A NET AND HOW ACCURATELY DOES THE NETest DIAGNOSE IT?
A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood.
Öberg K, Califano A, Strosberg JR, Ma S, Pape U, Bodei L, Kaltsas G, Toumpanakis C, Goldenring JR, Frilling A, Paulson S. Ann Oncol. 2020 Feb;31(2):202-212. doi: 10.1016/j.annonc.2019.11.003.
Malczewska A, Witkowska M, Wójcik-Giertuga M, Kuśnierz K, Bocian A, Walter A, Rydel M, Robek A, Pierzchała S, Malczewska M, Leś-Zielińska I, Czyżewski D, Ziora D, Pilch-Kowalczyk J, Zajecki W, Kos-Kudla B. Neuroendocrinology. 2020 Apr 24. doi: 10.1159/000508106.
Modlin IM, Kidd M, Bodei L, Drozdov I, Aslanian H. Am J Gastroenterol. 2015 Aug;110(8):1223-32. doi: 10.1038/ajg.2015.160.
A2. HOW EFFECTIVE IS THE NETest IN GEP-NENs?
Malczewska A, Witkowska M, Makulik K, Bocian A, Walter A, Pilch-Kowalczyk J, Zajęcki W, Bodei L, Oberg KE, Kos-Kudła B. Endocr Connect. 2019 Mar 1;8(4):442-53. doi: 10.1530/EC-19-0030.
van Treijen MJC, Korse CM, van Leeuwaarde RS, Saveur LJ, Vriens MR, Verbeek WHM, Tesselaar MET, Valk GD. Front Endocrinol (Lausanne). 2018 Dec 4;9:740. doi: 10.3389/fendo.2018.00740. eCollection 2018.
Utility of a ready-to-use PCR system for neuroendocrine tumor diagnosis.
Kidd M, Drozdov IA, Matar S, Gurunlian N, Ferranti NJ, Malczewska A, Bennett P, Bodei L, Modlin IM. PLoS One. 2019 Jun 27;14(6):e0218592. doi: 10.1371/journal.pone.0218592.
Modlin IM, Kidd M, Bodei L, Drozdov I, Aslanian H. Am J Gastroenterol. 2015 Aug;110(8):1223-32. doi: 10.1038/ajg.2015.160.
A3. IS THE NETest EFFECTIVE IN BP-NENs?
Filosso PL, Öberg K, Malczewska A, Lewczuk A, Roffinella M, Aslanian H, Bodei L. Eur J Cardiothorac Surg. 2020 Jun 1;57(6):1195-1202. doi: 10.1093/ejcts/ezaa018.
NETest Liquid Biopsy Is Diagnostic of Lung Neuroendocrine Tumors and Identifies Progressive Disease.
Malczewska A, Oberg K, Bodei L, Aslanian H, Lewczuk A, Filosso PL, Wójcik-Giertuga M, Rydel M, Zielińska-Leś I, Walter A, Suarez AL, Kolasińska-Ćwikła A, Roffinella M, Jamidar P, Ziora D, Czyżewski D, Kos-Kudła B, Ćwikła J. Neuroendocrinology. 2019;108(3):219-231. doi: 10.1159/000497037.
Filosso PL, Kidd M, Roffinella M, Lewczuk A, Chung KM, Kolasinska-Cwikla A, Cwikla J, Lowczak A, Doboszynska A, Malczewska A, Catalano M, Zunino V, Boita M, Arvat E, Cristofori R, Guerrera F, Oliaro A, Tesselaar M, Buikhuisen W, Kos-Kudla B, Papotti M, Bodei L, Drozdov I, Modlin I. Eur J Cardiothorac Surg. 2018 Mar 1;53(3):631-639. doi: 10.1093/ejcts/ezx386.
A4. CAN THE NETest IDENTIFY MICROMETASTATIC DISEASE?
Malczewska A, Bodei L, Kidd M, Modlin IM. J Clin Endocrinol Metab. 2019 Mar 1;104(3):867-872. doi: 10.1210/jc.2018-01804.
How does the NETest compare to other biomarkers?
A, Witkowska M, Wójcik-Giertuga M, Kuśnierz K, Bocian A, Walter A, Rydel M, Robek A, Pierzchała S, Malczewska M, Leś-Zielińska I, Czyżewski D, Ziora D, Pilch-Kowalczyk J, Zajecki W, Kos-Kudla B. Neuroendocrinology. 2020 Apr 24. doi: 10.1159/000508106.
van Treijen MJC, Korse CM, van Leeuwaarde RS, Saveur LJ, Vriens MR, Verbeek WHM, Tesselaar MET, Valk GD. Front Endocrinol (Lausanne). 2018 Dec 4;9:740. doi: 10.3389/fendo.2018.00740. eCollection 2018.
Assessment of NETest Clinical Utility in a U.S. Registry-Based Study.
Liu E, Paulson S, Gulati A, Freudman J, Grosh W, Kafer S, Wickremesinghe PC, Salem RR, Bodei L. Oncologist. 2019 Jun;24(6):783-790. doi: 10.1634/theoncologist.2017-0623. Epub 2018 Aug 29.
Modlin IM, Drozdov I, Alaimo D, Callahan S, Teixiera N, Bodei L, Kidd M. Endocr Relat Cancer. 2014 Aug;21(4):615-28. doi: 10.1530/ERC-14-0190.
Modlin IM, Kidd M, Bodei L, Drozdov I, Aslanian H. Am J Gastroenterol. 2015 Aug;110(8):1223-32. doi: 10.1038/ajg.2015.160.
How the NETest determines the success of surgery and identifies residual disease?
Laskaratos FM, Liu M, Malczewska A, Ogunbiyi O, Watkins J, Luong TV, Mandair D, Caplin M, Toumpanakis C. Endocrine. 2020 Apr 14. doi: 10.1007/s12020-020-02289-2.
Partelli S, Andreasi V, Muffatti F, Schiavo Lena M, Falconi M. Ann Surg Oncol. 2020 Apr 6. doi: 10.1245/s10434-020-08425-6.
Genç CG, Jilesen APJ, Nieveen van Dijkum EJM, Klümpen HJ, van Eijck CHJ, Drozdov I, Malczewska A, Kidd M, Modlin I. J Surg Oncol. 2018 Jul;118(1):37-48. doi: 10.1002/jso.25129.
Filosso PL, Kidd M, Roffinella M, Lewczuk A, Chung KM, Kolasinska-Cwikla A, Cwikla J, Lowczak A, Doboszynska A, Malczewska A, Catalano M, Zunino V, Boita M, Arvat E, Cristofori R, Guerrera F, Oliaro A, Tesselaar M, Buikhuisen W, Kos-Kudla B, Papotti M, Bodei L, Drozdov I, Modlin I. Eur J Cardiothorac Surg. 2018 Mar 1;53(3):631-639. doi: 10.1093/ejcts/ezx386.
Modlin IM, Frilling A, Salem RR, Alaimo D, Drymousis P, Wasan HS, Callahan S, Faiz O, Weng L, Teixeira N, Bodei L, Drozdov I, Kidd M. Surgery. 2016 Jan;159(1):336-47. doi: 10.1016/j.surg.2015.06.056.
Can the NETest identify if my disease is progressing?
van Treijen MJC, van der Zee D, Heeres BC, Staal FCR, Vriens MR, Saveur LJ, Verbeek WHM, Korse CM, Maas M, Valk GD, Tesselaar M. Neuroendocrinology. 2020 Jun 3. doi: 10.1159/000509091.
A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood.
Öberg K, Califano A, Strosberg JR, Ma S, Pape U, Bodei L, Kaltsas G, Toumpanakis C, Goldenring JR, Frilling A, Paulson S. Ann Oncol. 2020 Feb;31(2):202-212. doi: 10.1016/j.annonc.2019.11.003.
Assessment of NETest Clinical Utility in a U.S. Registry-Based Study.
Liu E, Paulson S, Gulati A, Freudman J, Grosh W, Kafer S, Wickremesinghe PC, Salem RR, Bodei L. Oncologist. 2019 Jun;24(6):783-790. doi: 10.1634/theoncologist.2017-0623. Epub 2018 Aug 29.
NETest Liquid Biopsy Is Diagnostic of Lung Neuroendocrine Tumors and Identifies Progressive Disease.
Malczewska A, Oberg K, Bodei L, Aslanian H, Lewczuk A, Filosso PL, Wójcik-Giertuga M, Rydel M, Zielińska-Leś I, Walter A, Suarez AL, Kolasińska-Ćwikła A, Roffinella M, Jamidar P, Ziora D, Czyżewski D, Kos-Kudła B, Ćwikła J. Neuroendocrinology. 2019;108(3):219-231. doi: 10.1159/000497037.
Filosso PL, Kidd M, Roffinella M, Lewczuk A, Chung KM, Kolasinska-Cwikla A, Cwikla J, Lowczak A, Doboszynska A, Malczewska A, Catalano M, Zunino V, Boita M, Arvat E, Cristofori R, Guerrera F, Oliaro A, Tesselaar M, Buikhuisen W, Kos-Kudla B, Papotti M, Bodei L, Drozdov I, Modlin I. Eur J Cardiothorac Surg. 2018 Mar 1;53(3):631-639. doi: 10.1093/ejcts/ezx386.
Pavel M, Jann H, Prasad V, Drozdov I, Modlin IM, Kidd M. Neuroendocrinology. 2017;104(2):170-182. doi: 10.1159/000446025.
Can the NETest tell me if my somatostatin analogues are effective?
Assessment of NETest Clinical Utility in a U.S. Registry-Based Study.
Liu E, Paulson S, Gulati A, Freudman J, Grosh W, Kafer S, Wickremesinghe PC, Salem RR, Bodei L. Oncologist. 2019 Jun;24(6):783-790. doi: 10.1634/theoncologist.2017-0623. Epub 2018 Aug 29.
Ćwikła JB, Bodei L, Kolasinska-Ćwikła A, Sankowski A, Modlin IM, Kidd M. J Clin Endocrinol Metab. 2015 Nov;100(11):E1437-45. doi: 10.1210/jc.2015-2792.
Can the NETest predict if PRRT will be effective?
PRRT genomic signature in blood for prediction of (177)Lu-octreotate efficacy.
Bodei L, Kidd MS, Singh A, van der Zwan WA, Severi S, Drozdov IA, Cwikla J, Baum RP, Kwekkeboom DJ, Paganelli G, Krenning EP, Modlin IM. Eur J Nucl Med Mol Imaging. 2018 Jul;45(7):1155-1169.
Bodei L, Kidd M, Modlin IM, Severi S, Drozdov I, Nicolini S, Kwekkeboom DJ, Krenning EP, Baum RP, Paganelli G. Eur J Nucl Med Mol Imaging. 2016 May;43(5):839-851. doi: 10.1007/s00259-015-3250-z.
Is PRRT working?
PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest.
Bodei L, Kidd MS, Singh A, van der Zwan WA, Severi S, Drozdov IA, Malczewska A, Baum RP, Kwekkeboom DJ, Paganelli G, Krenning EP, Modlin IM. Eur J Nucl Med Mol Imaging. 2020 Apr;47(4):895-906.
Are there independent validation studies?
Sensitivity and Specificity of the NETest: A Validation Study.
Al-Toubah T, Cives M, Valone T, Blue K, Strosberg JR. Neuroendocrinology. 2020 Jul 2. doi: 10.1159/000509866. Online ahead of print.
van Treijen MJC, van der Zee D, Heeres BC, Staal FCR, Vriens MR, Saveur LJ, Verbeek WHM, Korse CM, Maas M, Valk GD, Tesselaar M. Neuroendocrinology. 2020 Jun 3. doi: 10.1159/000509091.
Laskaratos FM, Liu M, Malczewska A, Ogunbiyi O, Watkins J, Luong TV, Mandair D, Caplin M, Toumpanakis C. Endocrine. 2020 Apr 14. doi: 10.1007/s12020-020-02289-2.
Partelli S, Falconi M. Ann Surg Oncol. 2020 May 27. doi: 10.1245/s10434-020-08464-z.
Partelli S, Andreasi V, Muffatti F, Schiavo Lena M, Falconi M. Ann Surg Oncol. 2020 Apr 6. doi: 10.1245/s10434-020-08425-6.
Malczewska A, Witkowska M, Wójcik-Giertuga M, Kuśnierz K, Bocian A, Walter A, Rydel M, Robek A, Pierzchała S, Malczewska M, Leś-Zielińska I, Czyżewski D, Ziora D, Pilch-Kowalczyk J, Zajecki W, Kos-Kudla B. Neuroendocrinology. 2020 Apr 24. doi: 10.1159/000508106.
A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood.
Öberg K, Califano A, Strosberg JR, Ma S, Pape U, Bodei L, Kaltsas G, Toumpanakis C, Goldenring JR, Frilling A, Paulson S. Ann Oncol. 2020 Feb;31(2):202-212. doi: 10.1016/j.annonc.2019.11.003.
van Treijen MJC, Korse CM, van Leeuwaarde RS, Saveur LJ, Vriens MR, Verbeek WHM, Tesselaar MET, Valk GD. Front Endocrinol (Lausanne). 2018 Dec 4;9:740. doi: 10.3389/fendo.2018.00740. eCollection 2018.
Assessment of NETest Clinical Utility in a U.S. Registry-Based Study.
Liu E, Paulson S, Gulati A, Freudman J, Grosh W, Kafer S, Wickremesinghe PC, Salem RR, Bodei L. Oncologist. 2019 Jun;24(6):783-790. doi: 10.1634/theoncologist.2017-0623. Epub 2018 Aug 29.
The development and history of the NETest
The Clinical Applications of a Multigene Liquid Biopsy (NETest) in Neuroendocrine Tumors.
Malczewska A, Kos-Kudla B, Kidd M, Drozdov I, Bodei L, Matar S, Oberg K, Modlin IM. Advances in Medical Sciences 65 (2020) 18–29.
Modlin IM, Kidd M, Malczewska A, Drozdov I, Bodei L, Matar S, Chung KM. Endocrinol Metab Clin N Am 47 (2018) 485–504.
Peer-Reviewed Articles
A variety of resources, including peer review research, presentations, and infographics about Wren Laboratories and the liquid biopsy tests we currently offer as well as diagnostics that are in development.
NETest expanded to China
In entering into a distribution agreement with Kindstar Globalgene Technology (Beijing, China), Wren Laboratories has expanded the global availability of our molecular neuroendocrine cancer diagnostic, the NETest. This partnership will double NETest utilization in 2024, providing oncologists for 300,000 NET cancer patients in China the ability to better understand their patient's tumor status and monitor therapy progression.
NETest Backgrounder Press Release
The NETest leverages both mRNA as its molecular foundation as well as Artificial Intelligence (AI) for gene assessment. introduced in 2014, the test has been utilized over 10,000 by oncologists and their patients to gain a better understanding of their Neuroendocrine Tumor activity and treatment progress.
PROSTest: ASCO-GU Abstract – PROSTest PCa sensitivity is 92.2 and 95
Development and validation of a Multigenomic Liquid Biopsy (PROSTest) for Prostate Cancer Detection
Neuroendocrinology – NETest Sensitivity and Specificity Validation Study
Secretory tumor markers traditionally measured in patients with neuroendocrine tumors (NET) are lacking sensitivity and specificity, and consequently they are of limited clinical utility.
Press Center
Welcome to the Wren Laboratories Press Center. Here you will find articles that have been written about our molecular diagnostics, our science, and our laboratory.
If you are associated with a media outlet and would like to contact us for background info or a quote, please contact Natalie Judd of Big Voice Communications. Natalie can be reached on 1 (203) 389-5223 or via email.
Smilow Cancer Hospital Closer to Free Ride Sponsor
This past Saturday, a team of Wren employees gathered at the Yale Bowl for the 13th Closer to...
Wren, NETest featured in GenomeWeb Article
The Wren Laboratories NETest and its recent expansion into the Chinese Market was the subject of a feature article by Forest Ray in GenomeWeb.com. The article characterized our decision to focus on mRNA as the basis for our diagnostic platform and also discusses a little bit about diagnostics in our pipeline, specifically our PROSTest.
NETest expanded to China
In entering into a distribution agreement with Kindstar Globalgene Technology (Beijing, China), Wren Laboratories has expanded the global availability of our molecular neuroendocrine cancer diagnostic, the NETest. This partnership will double NETest utilization in 2024, providing oncologists for 300,000 NET cancer patients in China the ability to better understand their patient's tumor status and monitor therapy progression.
NETest Backgrounder Press Release
The NETest leverages both mRNA as its molecular foundation as well as Artificial Intelligence (AI) for gene assessment. introduced in 2014, the test has been utilized over 10,000 by oncologists and their patients to gain a better understanding of their Neuroendocrine Tumor activity and treatment progress.
Additional Resources
Welcome to the Wren Laboratories Press Center. Here you will find articles that have been written about our molecular diagnostics, our science, and our laboratory.
If you are associated with a media outlet and would like to contact us for background info or a quote, please contact Natalie Judd of Big Voice Communications. Natalie can be reached on 1 (203) 389-5223 or via email.
Smilow Cancer Hospital Closer to Free Ride Sponsor
This past Saturday, a team of Wren employees gathered at the Yale Bowl for the 13th Closer to...
Wren, NETest featured in GenomeWeb Article
The Wren Laboratories NETest and its recent expansion into the Chinese Market was the subject of a feature article by Forest Ray in GenomeWeb.com. The article characterized our decision to focus on mRNA as the basis for our diagnostic platform and also discusses a little bit about diagnostics in our pipeline, specifically our PROSTest.
NETest expanded to China
In entering into a distribution agreement with Kindstar Globalgene Technology (Beijing, China), Wren Laboratories has expanded the global availability of our molecular neuroendocrine cancer diagnostic, the NETest. This partnership will double NETest utilization in 2024, providing oncologists for 300,000 NET cancer patients in China the ability to better understand their patient's tumor status and monitor therapy progression.
NETest Backgrounder Press Release
The NETest leverages both mRNA as its molecular foundation as well as Artificial Intelligence (AI) for gene assessment. introduced in 2014, the test has been utilized over 10,000 by oncologists and their patients to gain a better understanding of their Neuroendocrine Tumor activity and treatment progress.